PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 354 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR High Frequency of Germline ATM Variants in CLL November 11, 2022 Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies March 17, 2023 Touching a nerve: How neuroscience could advance our understanding of cancer December 1, 2021 EMA Recommends Extension of Indications for Ribociclib to Include Use in... November 5, 2024 Load more HOT NEWS Man Walks Entire Continent To Spread Awareness About Mental Health &... “White Bagging” Harmful to Patients, Requires Them to Use Insurance-Approved Formulary... Coping With War and Cancer: How to Take Care of Your... ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer?
